From a clinical point of view, the presence of an SF3B1 mutation appears to be an early event in MDS pathogenesis, manifests a distinct gene expression profile, and correlates with a favorable prognosis and a low risk of evolving into AML [25,26]. Here, SF3B1 is linked to myelodysplastic syndrome.